Anetumab ravtansine, an anti‐mesothelin antibody conjugated to a maytansine derivative tubulin inhibitor, was recently investigated in a randomised, open‐label Phase 2 trial in mesothelioma.15 Here, MSLN is linked to mesothelioma.